10-Q: Theriva Biologics Reports Second Quarter 2024 Results, Highlights Progress in Oncology Pipeline

Theriva Biologics reported its second quarter 2024 financial results, including a goodwill impairment charge, while also highlighting clinical advancements in its oncology programs.

Summary

• Theriva Biologics reported a net loss of $8.3 million for the three months ended June 30, 2024, and a net loss of $13.5 million for the six months ended June 30, 2024.
• The company experienced a goodwill impairment of $4.0 million during the quarter due to a sustained decline in the company's stock price.
• Research and development expenses were $3.0 million for the three months and $6.4 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents totaled $16.6 million as of June 30, 2024.
• The company believes its current cash will fund operations into the second quarter of 2025.
• The company is actively pursuing additional equity or debt financing.
• The company's lead product candidate, VCN-01, is being evaluated in a Phase 2 clinical study for pancreatic cancer and has shown positive topline data in a Phase 1 trial for retinoblastoma.
• The company sold 4.4 million shares of common stock through an at-the-market offering for net proceeds of $1.8 million during the six months ended June 30, 2024.

Sentiment

Score: 4

Explanation: The document contains both positive clinical updates and negative financial news, including a goodwill impairment and going concern issues. The overall sentiment is cautiously negative due to the financial risks.

Positives

• The FDA granted Fast Track Designation to VCN-01 for pancreatic cancer, which could expedite the drug's development and approval.
• Positive results from the Phase 1 retinoblastoma trial suggest VCN-01 has therapeutic potential for diverse cancers.
• The company's ongoing Phase 2b trial for pancreatic cancer is progressing with no safety concerns raised.
• Preclinical data supports the potential synergy of VCN-01 with chemotherapy regimens.
• The company has a strong intellectual property portfolio with over 130 patents and 55 pending applications.

Negatives

• The company reported a net loss of $13.5 million for the six months ended June 30, 2024.
• A goodwill impairment charge of $4.0 million was recorded due to a decline in the company's stock price.
• The company's independent auditor has raised substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's cash position is only expected to fund operations into the second quarter of 2025, requiring additional financing.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company may need to delay, reduce, or eliminate certain development programs if funding is not secured.
• The company's stock price may be negatively impacted by the material weaknesses in internal controls.
• The company's stock may be delisted from the NYSE American if it fails to meet continued listing requirements.
• The company's future clinical trials will require significant financing or a significant partnership.

Future Outlook

The company anticipates its current cash will fund operations into the second quarter of 2025 and is actively pursuing additional equity or debt financing. The company expects research and development expenses to increase as it continues enrollment in its VIRAGE Phase 2 clinical trial of VCN-01 in PDAC, advances its VCN-01 program in retinoblastoma, expands GMP manufacturing activities for VCN-01, and continues supporting its other preclinical and discovery initiatives.

Management Comments

• Management believes its plan, which is focused on the advancement of VCN-01 will allow us to meet our financial obligations, further advance key products, and maintain our planned operations.
• Management believes the efforts taken to date and the planned remediation will improve the effectiveness of our internal control over financial reporting.

Industry Context

The company's focus on oncolytic virotherapy aligns with the growing interest in novel cancer treatments that harness the power of the immune system. The company's lead product candidate, VCN-01, is being developed for difficult-to-treat cancers, which represents a significant unmet medical need.

Comparison to Industry Standards

• The company's cash burn rate is consistent with other clinical-stage biotech companies, but the company's cash runway is shorter than some of its peers.
• The company's clinical trial progress is in line with industry standards, but the company's financial position is weaker than some of its competitors.
• The company's intellectual property portfolio is strong, which is a key asset for a biotech company.
• The company's goodwill impairment charge is a negative signal, but it is not uncommon for biotech companies to experience such charges.

Related Party Transactions

• The company paid compensation to MaryAnn Shallcross of $38,000 and $76,000 during the three and six months ended June 30, 2024, respectively.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be impacted by potential delays or reductions in development programs if funding is not secured.
• Customers (potential patients) may benefit from the company's clinical advancements in cancer treatments.
• Suppliers and creditors may be impacted by the company's financial instability.

Next Steps

• The company will continue enrollment in its VIRAGE Phase 2 clinical trial of VCN-01 in PDAC.
• The company will advance its VCN-01 program in retinoblastoma.
• The company will expand GMP manufacturing activities for VCN-01.
• The company will continue supporting its other preclinical and discovery initiatives.
• The company will seek additional equity or debt financing.
• The company will continue to remediate material weaknesses in internal controls.

Key Dates

Keywords

Theriva Biologics, VCN-01, Oncolytic Virus, Pancreatic Cancer, Retinoblastoma, Clinical Trial, Fast Track Designation, Goodwill Impairment, Research and Development, Capital Raise